what is a microdose of retatrutide Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, being sold openly across the internet and prescribed by licensed physicians online and Retatrutide Half Life: A Doctor

The half-life is 5 days, and it is administered by subcutaneous injection once a week

GLP-1 and GIP-based therapies may be appropriate for individuals with Type 2 diabetes, insulin resistance, or those who are overweight (BMI 2730+) with at least one weight-related condition such as high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease

Meanwhile, semaglutide would require an 85% price reduction to achieve cost-effectiveness despite superior results

Readers are strongly advised to consult with a qualified healthcare professional before making any decisions regarding their health, including the use of GLP-1 receptor agonists or any other medication discussed herein